Wide Ranks

GH

Guardant Health, Inc.

35.10

Top Statistics
Market Cap 4 B Forward PE -16.85 Revenue Growth 33.90 %
Current Ratio 6.22 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -74.02 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -12.03 Enterprise / Revenue 6.71 Price To Sales Trailing12 Months 6.26
Profitability
Profit Margins -74.02 % Operating Margins -61.10 %
Balance Sheet
Total Cash 1 B Total Cash Per Share 8.34 Total Debt 1 B
Total Debt To Equity Current Ratio 6.22 Book Value Per Share -0.4880
All Measures
Short Ratio 456.00 % Message Board Id finmb_256906841 Fax 888 974 4258
Shares Short Prior Month 13 M Return On Equity -6.09 City Palo Alto
Uuid 6848ae6f-8e78-3062-b1b2-3476c9ecd258 Previous Close 34.37 First Trade Date Epoch Utc 1 B
Book Value -0.4880 Beta 1.11 Total Debt 1 B
Volume 986748 Fifty Two Week Low 15.81 Total Cash Per Share 8.34
Total Revenue 692 M Shares Short Previous Month Date 1 B Target Median Price 42.00
Max Age 86400 Recommendation Mean 1.41 Sand P52 Week Change 0.3133
Operating Margins -61.10 % Target Mean Price 43.00 Net Income To Common -512409984
Short Percent Of Float 0.0792 Implied Shares Outstanding 123 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 2 M Average Volume10days 2 M
Total Cash 1 B Next Fiscal Year End 1 B Revenue Per Share 5.70
Held Percent Insiders 0.0456 Ebitda Margins -55.80 % Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 34.37
Target Low Price 34.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 24.81
Open 35.05 Free Cashflow -151071872 State CA
Dividend Yield 0.00 % Return On Assets -0.1608 Time Zone Short Name EST
Trailing Eps -4.28 Day Low 34.53 Address1 3100 Hanover Street
Shares Outstanding 123 M Price Hint 2 Target High Price 60.00
Website https://guardanthealth.com 52 Week Change 0.3945 Average Volume 2 M
Forward Eps -2.71 Recommendation Key strong_buy Compensation As Of Epoch Date 1 B
Quick Ratio 566.90 % Is_sp_500 False Regular Market Day High 35.56
Profit Margins -74.02 % Fifty Two Week High 37.04 Day High 35.56
Shares Short 9 M Regular Market Open 35.05 Industry Key diagnostics-research
Earnings Growth 0.00 % Enterprise To Revenue 6.71 Revenue Growth 33.90 %
Shares Percent Shares Out 0.0760 Operating Cashflow -254072992 Currency USD
Time Zone Full Name America/New_York Market Cap 4 B Is_nasdaq_100 False
Zip 94304 Quote Type EQUITY Industry Diagnostics & Research
Long Name Guardant Health, Inc. Regular Market Day Low 34.53 Held Percent Institutions 1.05
Current Price 35.10 Enterprise To Ebitda -12.03 Financial Currency USD
Current Ratio 6.22 Gross Margins 60.31 % Industry Disp Diagnostics & Research
Number Of Analyst Opinions 20 Country United States Float Shares 111 M
Two Hundred Day Average 24.65 Enterprise Value 4 B Price To Sales Trailing12 Months 6.26
Forward PE -16.85 Regular Market Volume 986748 Ebitda -386308992
Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally.

The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.

It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection.

In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment.

The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research.

The company was incorporated in 2011 and is headquartered in Palo Alto, California.